1979 High School Diploma at ITAS. “GB Cerletti” Conegliano (Italy)

1983 Dr. Degree Biological Sciences, University of Padua.

1985-1988 Project leader, Sclavo Research Center (actually Novartis) Siena Italy

1988-1993 Head Molecular Biology Fidia Farmaceuticals , Abano Terme, Italy.

1993-1994 Head Molecular Biology, Dompè Farmeceutici, L’Aquila, Italy.

1994-2002 Research Assistant, Department of Biological Chemistry, CRIBI, University of Padua.

2002-2010 Associate Professor, Department of Scienze Sperimentali Veterinarie, University of Padua.

2011 to present Associate Professor, Department of Biomedical Science, University of Padua

Alessandro Negro has a long-standing interest in the synthesis and expression of recombinant proteins in E. coli, Baculovirus and CHO cells with development several patents on growth factors of nervous system when he worked in several companies. From 1994, back to University of Padua, he focused its interest on heterologous expression of genes in E. coli linked to neurodegenerative diseases. The neurodegenerative diseases are believed for result from the accumulation of amyloid fibrils formed by misfolded proteins, and here he focus its research, concerns the molecular mechanisms underlying of neurodegenerative disorders such as Alzheimer's Parkinson's disease caused by accumulation of specific proteins such as prion protein, α-Synuclein, DJ-1 and Parkin. TAT protein transduction is a novel method of delivering biologically active proteins into cells and tissue through the fusion of a protein transduction domain to the protein of interest. This method has been applied as transducer these proteins also in cells of animals, plants and fungi. More recently, through the metabolic engineering of B. subtilis and B. megaterium, he has product hyaluronic acid in these procariotic cells.

Alessandro Negro has published 90 peer-reviewed papers on international journals (2680 citations, H-index 29).
He also has published 19 international patents on recombinant protein expression.

  • 60%
  • Fidia Farmaceutici Project Hyaluronic acid.